Clinical Cancer Research, Vol 3, Issue 10 1831-1835, Copyright © 1997 by American Association for Cancer Research

ARTICLES

p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung

T Komiya, Y Hosono, T Hirashima, N Masuda, T Yasumitsu, K Nakagawa, M Kikui, A Ohno, M Fukuoka and I Kawase
Departments of Internal Medicine, Pathology, and Surgery, Osaka Prefectural Habikino Hospital, Habikino City, Osaka 583, Japan.

Although p21 WAF1/Cip1 expression has been detected immunohistochemically in non-small cell lung cancer (NSCLC), the associations between p21 expression and clinical characteristics are unknown. To determine the association between p21 expression and clinical features, p21 expression was immunohistochemically analyzed in paraffin-embedded tumor samples from 137 patients with curatively resected NSCLC. p21 expression, indicating normal p21 function, was detected in 48 (35.0%) of the 137 patients with curatively resected NSCLC and was detected more frequently in patients with stage I or II disease (40.2%) than in those with stage IIIA disease (22.5%; P = 0.0483). There was no difference in the positive rate between squamous cell carcinoma [SCC; 15 of 48 (31.3%)] and adenocarcinoma [30 of 77 (39.0%)]. For SCC, patients with tumors expressing p21 survived longer than did those with tumors negative for p21 expression; however, the corresponding survival time was not significant for adenocarcinoma. On the other hand, p53 expression, detected in 58 (42.3%) of these patients, did not act as any predictor for prognosis in either SCC or adenocarcinoma. Our findings suggest that the presence of p21 expression is associated with favorable prognosis in SCC and may be useful in obtaining candidates for adjuvant therapies from among patients with SCC.

This article has been cited by other articles:

				A. L. Gartel Is p21 an oncogene? Mol. Cancer Ther., June 1, 2006; 5(6): 1385 - 1386. [Full Text] [PDF]

				S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986. [Abstract] [Full Text] [PDF]

				L. J. Hofseth The adaptive imbalance to genotoxic stress: genome guardians rear their ugly heads Carcinogenesis, October 1, 2004; 25(10): 1787 - 1793. [Abstract] [Full Text] [PDF]

				S. Han, N. Sidell, P. B. Fisher, and J. Roman Up-regulation of p21 Gene Expression by Peroxisome Proliferator-Activated Receptor {gamma} in Human Lung Carcinoma Cells Clin. Cancer Res., March 15, 2004; 10(6): 1911 - 1919. [Abstract] [Full Text] [PDF]

				H. Swede, Y. Dong, M. Reid, J. Marshall, and C. Ip Cell Cycle Arrest Biomarkers in Human Lung Cancer Cells After Treatment with Selenium in Culture Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1248 - 1252. [Abstract] [Full Text]

				K. Kameyama, C.-l. Huang, D. Liu, D. Masuya, T. Nakashima, S. Sumitomo, Y. Takami, M. Kinoshita, and H. Yokomise Reduced ING1b Gene Expression Plays an Important Role in Carcinogenesis of Non-Small Cell Lung Cancer Patients Clin. Cancer Res., October 15, 2003; 9(13): 4926 - 4934. [Abstract] [Full Text] [PDF]

				T. Shoji, F. Tanaka, T. Takata, K. Yanagihara, Y. Otake, N. Hanaoka, R. Miyahara, T. Nakagawa, Y. Kawano, S. Ishikawa, et al. Clinical Significance of p21 Expression in Non-Small-Cell Lung Cancer J. Clin. Oncol., September 15, 2002; 20(18): 3865 - 3871. [Abstract] [Full Text] [PDF]

				M. D. Brundage, D. Davies, and W. J. Mackillop Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress Chest, September 1, 2002; 122(3): 1037 - 1057. [Abstract] [Full Text] [PDF]

				X. Xie, O. P. F. Clausen, and M. Boysen Prognostic Significance of p21WAF1/CIP1 Expression in Tongue Squamous Cell Carcinomas Arch Otolaryngol Head Neck Surg, August 1, 2002; 128(8): 897 - 902. [Abstract] [Full Text] [PDF]

				G. Pruneri, L. Pignataro, N. Carboni, R. Buffa, D. Di Finizio, B. M. Cesana, and A. Neri Clinical Relevance of Expression of the CIP/KIP Cell-Cycle Inhibitors p21 and p27 in Laryngeal Cancer J. Clin. Oncol., October 1, 1999; 17(10): 3150 - 3159. [Abstract] [Full Text] [PDF]

				S. Natsugoe, S. Nakashima, M. Matsumoto, C. Xiangming, H. Okumura, F. Kijima, S. Ishigami, Y. Takebayashi, M. Baba, S. Takao, et al. Expression of p21WAF1/Cip1 in the p53-dependent Pathway Is Related to Prognosis in Patients with Advanced Esophageal Carcinoma Clin. Cancer Res., September 1, 1999; 5(9): 2445 - 2449. [Abstract] [Full Text] [PDF]

				A.-M. C. Dingemans, M. A. Witlox, R. A. L. M. Stallaert, P. van der Valk, P. E. Postmus, and G. Giaccone Expression of DNA Topoisomerase II{{alpha}} and Topoisomerase II{beta} Genes Predicts Survival and Response to Chemotherapy in Patients with Small Cell Lung Cancer Clin. Cancer Res., August 1, 1999; 5(8): 2048 - 2058. [Abstract] [Full Text] [PDF]